MPM BioImpact LLC
CIK 1687078 · last filed 2025-04-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$167.26M
Companies
5
Total Filings
16
Lifetime Open-Market Net
-$43.42M
Filer Profile
Reported Address
399 BOYLSTON STREET, SUITE 1100BOSTON, MA 02116
Phone
(617) 425-9200
State of Incorporation
DE
Formerly Known As
BioImpact Capital LLC (2021–2023)
MPM Oncology Impact Management LP (2017–2021)
Related Filers
Oncology Impact Fund (Cayman) Management L.P. — 66 joint filings, latest 2025-12-04
UBS Oncology Impact Fund L.P. — 66 joint filings, latest 2025-12-04
ANSBERT GADICKE — 46 joint filings, latest 2025-12-04
MPM Oncology Impact Management GP LLC — 32 joint filings, latest 2021-08-25
MPM ONCOLOGY INNOVATIONS FUND LP — 12 joint filings, latest 2025-12-04
MPM Oncology Innovations Fund GP LLC — 12 joint filings, latest 2025-12-04
MPM ASSET MANAGEMENT LLC — 10 joint filings, latest 2025-12-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HOWL | 10%+ Owner | 6,718,670 | $0.99 | $6.64M | -$32.2K | 1 | 2025-04-30 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 4,943,551 | $10.15 | $50.18M | -$24.60M | 7 | 2021-12-02 |
| CGEM | 10%+ Owner | 7,648,268 | $21.00 | $160.61M | -$12.62M | 5 | 2021-09-20 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | 10%+ Owner | 637,490 | $23.01 | $14.67M | -$7.08M | 2 | 2021-06-02 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 951,857 | $18.62 | $17.72M | $904.0K | 1 | 2017-11-06 |
Recent Filings · Page 2 of 2
16 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-31 | CGEM | Sell (S) | −133,074 | -$3.89M | EDGAR |
| 2021-06-02 | Harpoon Therapeutics, Inc. (HARP) Delisted | Sell (S) | −287,470 | -$5.93M | EDGAR |
| 2021-05-06 | Harpoon Therapeutics, Inc. (HARP) Delisted | Sell (S) | −50,860 | -$1.15M | EDGAR |
| 2021-04-09 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | −288,260 | -$6.50M | EDGAR |
| 2020-07-30 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | +30,311,100 | $30.40M | EDGAR |
| 2017-11-06 | Viracta Therapeutics, Inc. (SNSS) Delisted | Buy (P) | +326,000 | $904.0K | EDGAR |
Showing 11–16 of 16
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.